NCT02527174 A Study of Volasertib Plus Induction Chemotherapy for Acute Myeloid Leukemia Status WITHDRAWN Phase PHASE1
NCT02523976 Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia Status COMPLETED Phase PHASE2
NCT02521493 Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT02504359 Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma Status COMPLETED Phase PHASE1
NCT02488408 A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDS Status COMPLETED Phase PHASE1/PHASE2
NCT02484391 CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma Status COMPLETED Phase PHASE1
NCT02483000 Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies Status TERMINATED Phase PHASE1
NCT02481310 Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma Status UNKNOWN Phase PHASE1/PHASE2
NCT02472626 6,8-Bis(Benzylthio)Octanoic Acid, Cytarabine, and Daunorubicin Hydrochloride in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia Status WITHDRAWN Phase PHASE1/PHASE2
NCT02464657 Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Status COMPLETED Phase PHASE1/PHASE2
NCT02443077 Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT02441803 Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML) Status COMPLETED Phase PHASE2
NCT02440568 AML-02: Omacetaxine With Standard-of-Care Induction With Cytarabine & Idarubicin in Newly-Diagnosed AML Patients Status TERMINATED Phase PHASE1/PHASE2
NCT02433483 Microtransplantation to Treat Refractory or Relapsed Hematologic Malignancies in Younger Patients Status TERMINATED Phase PHASE2
NCT02432872 Treatment of Older Adult Acute Myeloid Leukemia Patients Aged 55 to 65 Years Status UNKNOWN Phase NA
NCT02427620 Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT02420717 Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia Status TERMINATED Phase PHASE2
NCT02419755 Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies Status TERMINATED Phase PHASE2